Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Jersey Shore Medical Center — Neptune City, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Newark Beth Israel Medical Center — Newark, New Jersey
- Saint Joseph's Regional Medical Center — Paterson, New Jersey
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Thomas Jefferson Univ Hosp — Haddonfield, New Jersey
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in New Jersey: - Hackensack University Medical Center, HMH — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in New Jersey: - Summit Medical Group Cancer Center ( Site 0007) — Florham Park, New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016) — Hackensack, New Jersey
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in New Jersey: - Rutgers Biomedical and Health Sciences — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in New Jersey: - John Theurer Cancer Center / Hackensack University — Hackensack, New Jersey
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Cooper Hospital University Medical Center — Camden, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Cooper Hospital University Medical Center — Camden, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Newark Beth Israel Medical Center — Newark, New Jersey
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Jersey Shore Medical Center — Neptune City, New Jersey
- Saint Peter's University Hospital — New Brunswick, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Saint Joseph's Regional Medical Center — Paterson, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in New Jersey: - Memorial Sloan-Kettering Cancer Center (MSKCC) - Basking Ridge — Basking Ridge, New Jersey
- Astera Cancer Care — Edison, New Jersey
- John Theurer Cancer Center — Hackensack, New Jersey
- Hackensack University Medical Center — Hackensack, New Jersey
- Atlantic Health System / Morristown Medical Center — Morristown, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in New Jersey: - Hunterdon Hematology Oncology — Flemington, New Jersey
- Summit Medical Group — Florham Park, New Jersey
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in New Jersey: - John Theurer Cancer Center - Hackensack Meridian Health — Hackensack, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax a…
Sponsor: OncoVerity, Inc.
NCT ID: NCT06384261
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey ( Site 1008) — New Brunswick, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transform…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04728893
Sites in New Jersey: - Astera Cancer Care ( Site 2732) — East Brunswick, New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704) — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer o…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06561360
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1 Recruiting Industry
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilte…
Sponsor: Oryzon Genomics S.A.
NCT ID: NCT05546580
Sites in New Jersey: - Rutgers, The State University — Piscataway, New Jersey
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Robert Wood Johnson/Cancer Institute of New Jersey — New Brunswick, New Jersey
Recruiting Network
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…
Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
NA Recruiting Academic/Other
Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers are doing this study to find out whether telehealth music th…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07052916
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) — Montvale, New Jersey